E
Ernexa Therapeutics
Harnessing the power of cytokines to restore immune function
About Ernexa Therapeutics
Brooklyn ImmunoTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer and immunologic diseases. The company's primary focus is on IRX-2, a novel human cell-derived hd IL-2 based therapy designed to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. IRX-2 has shown promising results in Phase 2a clinical trials for head and neck cancer, demonstrating an increase in tumor-infiltrating lymphocytes and an associated survival benefit. Brooklyn ImmunoTherapeutics operates in the biopharmaceutical market, targeting healthcare providers and researchers specializing in oncology and immunotherapy. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
News
Open roles
Ernexa Therapeutics in the New York City ecosystem
The Ernexa Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ernexa Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ernexa Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


